BioSpace News Archive

Results of prospective study using graft-derived circulating free DNA as biomarker for rejection in organ transplantation presented at the American Association of Clinical Chemistry (AACC) annual meeting

American Academy of Ophthalmology and American Academy of Optometry join the Centers for Disease Control and Prevention to promote healthy contact lens habits to protect sight

Alkermes plc announced that its corporate presentation will be webcast live at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET (3:30 p.m. BST) from Boston.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2018.

Presented Data from Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Overall Response Rate of 83% and Durable Ongoing Reponses up to 22 Months

REGENXBIO Inc. announced that it will host a conference call on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018 and recent operational highlights.

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational, once-daily norepinephrine and serotonin reuptake inhibitor (NSRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH).

AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston.

Deciphera Pharmaceuticals, Inc. today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018.

Conference call scheduled today at 9:00 a.m. ET